Objective: To clarify the associations between polyclonal serum free light chain (sFLC) levels and adverse outcomes in patients with chronic kidney disease (CKD) by conducting a systematic review and individual patient data meta-analyses. Patients and Methods: On December 28, 2016, we searched 4 databases (MEDLINE, Embase, CINAHL, and PubMed) and conference proceedings for studies presenting independent analyses of associations between sFLC levels and mortality or progression to end-stage renal disease (ESRD) in patients with CKD. Study quality was assessed in 5 domains: sample selection, measurement, attrition, reporting, and funding. Results: Five prospective cohort studies were included, judged moderate to good quality, involving 3912 participants in total. In multivariable meta-analyses, sFLC (kappaþlambda) levels were independently associated with mortality (5 studies, 3680 participants; hazard ratio [HR], 1.04 [95% CI, 1.03-1.06] per 10 mg/L increase in sFLC levels) and progression to ESRD (3 studies, 1848 participants; HR, 1.01 [95% CI, 1.00-1.03] per 10 mg/L increase in sFLC levels). The sFLC values above the upper limit of normal (43.3 mg/L) were independently associated with mortality (HR, 1.45 [95% CI, 1.14-1.85]) and ESRD (HR, 3.25 [95% CI,). Conclusion: Higher levels of sFLCs are independently associated with higher risk of mortality and ESRD in patients with CKD. Future work is needed to explore the biological role of sFLCs in adverse outcomes in CKD, and their use in risk stratification.
C hronic kidney disease (CKD) is common, with an estimated prevalence of 3% to 17% in Europe and 15% in the United States. 1, 2 It is associated with adverse health outcomes, including acute kidney injury, progression to end-stage renal disease (ESRD), cardiovascular disease (CVD), and mortality. [3] [4] [5] [6] Estimated glomerular filtration rate (eGFR) and albuminuria are wellestablished prognostic factors in CKD that are measured routinely in clinical practice and used for risk stratification. However, there is major interest in the study of novel prognostic factors and biomarkers that could potentially improve current risk stratification methods and that may provide insights into the underlying mechanisms of adverse outcomes associated with CKD and, thereby, identify potential therapeutic targets. 7 Polyclonal serum free light chains (sFLCs) are produced by cells of the B-cell lineage and undergo renal metabolism. Thus, sFLC levels are increased in CKD, and there are plausible mechanisms by which they may be directly implicated in the associated risks of mortality and ESRD. 8 However, studies published to date have reported results that are inconsistent, with variable adjustment for confounding factors, and so there remains uncertainty whether sFLC levels are independently associated with adverse outcomes in CKD.
To address this issue, we performed a systematic review and meta-analysis of individual patient data to summarize and synthesize published data on the association between sFLC levels and mortality as well as progression to ESRD in patients with CKD.
PATIENTS AND METHODS
This study was conducted in accordance with published guidelines for systematic review, analysis, and reporting of meta-analyses of observational studies. 9 It was registered a priori with PROS-PERO, an international database of prospectively registered systematic reviews (accessible at http:// www.crd.york.ac.uk/prospero/display_record. asp?ID¼CRD42015025195).
Studies meeting the following criteria were included:
d Types of studies: Quantitative studies presenting an independent analysis of the association between sFLCs and mortality or ESRD in humans with CKD. Case reports and qualitative studies were not included. No restrictions on language, publication date, or publication status were imposed. d Participants: Individuals with CKD. Participants were excluded if they were receiving dialysis or if they had monoclonal gammopathy (monoclonal gammopathy of undetermined significance or multiple myeloma). d Exposure: Polyclonal sFLC concentration. d Outcomes: 1) All-cause mortality and 2) ESRD, defined as initiation of renal replacement therapy (RRT).
Literature Review
We searched 4 databases (MEDLINE, 1946-present; Embase, 1947-present; CINAHL; and PubMed) using terms for CKD and immunoglobulin light chains using MeSH and related terms as free text, and we also included a term to exclude studies with myeloma in the title. 
Outcome Measures
Primary outcome measures were the adjusted hazard ratio (HR) for all-cause mortality and progression to ESRD.
Statistical Analyses
Individual patient data were obtained from all the included studies. All the studies had included the following baseline variables: age, sex, diabetes mellitus (DM), CVD, systolic blood pressure (SBP), modification of diet in renal disease formula (MDRD) eGFR, serum albumin level, calcium level, phosphate level, renin-angiotensin-aldosterone system (RAAS) inhibitor use, and sFLC levels (defined for these analyses as combined sFLCs: k plus l). Descriptive statistics were used to show the characteristics of individuals in the combined study population.
A meta-analysis of individual patient data was conducted using 2 distinct methods in view of the different ways in which individual studies had analyzed sFLC levels, the differing covariates used in the individual analyses, and the limited number of people in 2 studies with sFLC levels of 43.3 mg/L or less (95th percentile of the reference range) (only 5 [6%] and 10 [3%] in the studies by Desjardins et al 12 and Haynes et al, 13 respectively). Individual data sets from each study were combined for common variables, and KaplanMeier analysis and univariate and multivariable Cox regression models were conducted on combined data to explore relationships between sFLC levels greater than 43.3 mg/L and all-cause mortality and ESRD. Study of origin was included as a fixed effect covariable to account for study heterogeneity. A high proportion of participants in the studies by Ritchie et al 14 (39%) and Desjardins et al 12 (100%) were missing values for urine albumin to creatinine ratio (uACR); uACR was, therefore, not included in the main analyses. A sensitivity analysis was conducted for survival analysis in those with complete uACR data (n¼3103) (Supplemental Table 2 , available online at http://www.mayoclinicproceedings.org). To address the potential for effect modification of survival and progression by comorbidity and age, interaction terms were tested between DM and RAAS inhibitor use, DM and CVD, and age and CVD. We also tested interactions between race and DM and between RAAS inhibitor use and DM for ESRD analyses. The individual patient data meta-analyses were conducted using IBM SPSS Statistics for Windows, Version 22.0 (IBM Corp).
A second, more traditional, meta-analysis of individual studies was conducted to demonstrate the association of a 10 mg/L rise in sFLC levels with all-cause mortality and ESRD (for studies that included progression to RRT as an outcome) using inverse varianceeweighted fixed effects models. These analyses controlled for age, sex, MDRD eGFR, CVD, DM, and serum albumin level. A 10 mg/L increase was chosen because it was perceived to reflect a clinically meaningful change in sFLC levels while allowing broader interpretation than the binary 43.3 mg/L threshold. Fixed effects models were used in view of the small number of studies. I 2 statistics were calculated as a measure of study heterogeneity. Forest plots were used to combine and display the results. The traditional meta-analyses were conducted using STATA SE version 14 (StataCorp LLC).
RESULTS
We identified 1554 citations meeting the search criteria. Title and abstract review led to the exclusion of 1542 articles. Full texts were obtained and reviewed for the remaining 12 articles, of which 7 were excluded, leaving 5 studies for inclusion ( Figure 1 ). [12] [13] [14] [15] [16] 12 included 44 participants undergoing dialysis. After excluding these, 3833 participants remained, with all CKD stages represented (except for patients receiving dialysis or with a kidney transplant). Four studies were conducted in the United Kingdom, and 1 in France. Four studies recruited participants from secondary care nephrology clinics, and 1 from primary care. All the studies had used the Freelite assay (The Binding Site Group Ltd) to measure sFLC levels. Statistical analysis methods varied among studies: 3 studies assessed sFLC levels as a categorical variable (using median, quartiles, or upper limit of the reference range as cutoff values) and 2 studies analyzed sFLC levels as a continuous variable. Four studies combined kappa (k) and lambda (l) sFLCs for survival analyses, and 1 study analyzed k and l FLCs separately. All the studies evaluated associations between sFLC levels and all-cause mortality; 2 also evaluated progression to ESRD (Table 1) . One study defined ESRD as initiation of RRT, and 1 as initiation of RRT or reaching an eGFR of 9 mL/min/1.73 m 2 or less.
The overall risk of bias was judged to be low for the study by Ritchie et al 14 and moderate for the other 4 studies. Assessments of the risk of bias in the domains of sample selection (including risk of residual confounding), measurement, attrition (dropout), reporting, and funding are presented individually for each study in Supplemental Table 1 .
Findings From Individual Studies All-Cause Mortality. Assi et al 16 (n¼1695) assessed sFLC levels as a categorical variable, using the upper limit of the reference range for sFLC in the healthy population (>43.3 mg/L) as a cutoff value. An sFLC level greater than 43.3 mg/L was associated with a 3-fold increase in mortality risk in univariate Cox regression analysis, and this increased risk remained significant, although attenuated, in their fully adjusted model. Desjardins et al 12 (n¼133) analyzed k and l FLCs separately, using their respective medians as cutoff values. A k FLC level higher than the median was associated with an increased risk of mortality on univariate analysis, but this association did not remain after adjusting for age and eGFR. A l FLC level higher than the median was not associated with an increased risk of mortality on either univariate or multivariable analysis. Haynes et al 13 (n¼364) analyzed sFLC levels on a log scale (both combined and k and l FLCs separately) and showed weak evidence of an association between l FLC level and mortality risk, with no significant effect of sFLC level after full adjustment.
Hutchison et al 15 (n¼848) assessed sFLC levels as a categorical (in quintiles) and a continuous variable. On univariate analysis, a 1-U increase in sFLC level on a log scale was associated with a 3-fold increased risk of death. This risk remained significant after full adjustment. Ritchie et al 14 (n¼872) analyzed sFLC levels by quartiles, and on univariate analysis those in the third and fourth quartiles had a statistically significantly increased mortality risk compared with those in the lowest quartile. This association remained in their multivariable model (Table 1) .
Progression to ESRD. Haynes et al 13 reported an increased risk of ESRD in a model adjusted for age and sex, but the statistical significance no longer remained after further adjustment for eGFR. Ritchie et al 14 identified an increased risk of ESRD in those in the highest 2 quartiles of sFLCs in the univariate and multivariable models (Table 1) .
Meta-analysis
Of the 3912 participants included in the 5 studies, 3815 (97.5%) had a value for sFLCs and 3680 (94.1%) had complete data for exposure and mortality outcome variables and, hence, were included in the survival analyses ( All the studies were conducted in hospital nephrology clinics except that by Assi et al, 16 which was conducted in primary care. c Statistically significant. greater than 43.3 mg/L were all positively associated with all-cause mortality. Use of RAAS inhibitors was associated with a lower risk of allcause mortality (Table 3 ). The results of the unadjusted Kaplan-Meier analysis demonstrate the difference in cumulative survival by sFLC status above and below the 43.3 mg/L threshold (Figure 2 ). In the final multivariable model, after adjustment for age, sex, DM, CVD, eGFR, albumin level, calcium level, taking RAAS inhibitors, and sFLC level, with original study as a fixed effect, the associations with age, sex, DM, CVD, eGFR, albumin level, and sFLC level remained (Table 3 ). An sFLC concentration greater than 43.3 mg/L was associated with an HR of 1.45 (95% CI, 1.14-1.85; P<.001). The sensitivity analysis in those with uACR values found no difference in the association between sFLC levels and all-cause mortality (Supplemental Table 2 ). No interactions were identified. A 10 mg/L rise in sFLC levels was associated with an overall increased risk of 4% (95% CI, 3%-6%) for all-cause mortality on meta-analysis of the 5 individual studies (Figure 3 ), although significant heterogeneity was detected (I 2 ¼ 62.6%; P¼.03).
Progression to ESRD. Although only 2 studies had reported progression to ESRD as an outcome, 3 studies had collected data on this (combined n¼2084). [13] [14] [15] We conducted combined analyses on the 1848 participants with complete data for exposure and ESRD as an outcome.
On univariate Cox regression analysis, younger age, nonwhite race, DM, higher SBP, increased albuminuria, lower eGFR, lower albumin level, lower calcium level, taking RAAS inhibitors, and sFLC level greater than 43.3 mg/L were all positively associated with progression to ESRD. In the final multivariable model, after adjustment for age, sex, race, DM, SBP, eGFR, albumin level, calcium level, taking RAAS inhibitors, and sFLC level, with original study as a fixed effect, the associations with age, SBP, eGFR, albumin level, calcium level, and sFLC level remained (Table 4 ). An sFLC concentration greater than 43.3 mg/L was associated with an HR of 3.25 (95% CI, 1.32-7.99; P¼.01). No interactions were identified. A 10 mg/L increase in sFLC levels was associated with an overall increased risk of progression to ESRD of 1% (95% CI, 0%-3%) (Figure 3 ). There was evidence of considerable heterogeneity across studies (I 2 ¼58.8%; P¼.09).
DISCUSSION
This is the first systematic review and meta-analysis examining the association between polyclonal sFLC levels and adverse outcomes in patients with CKD. We believe that it includes the totality of data published to date: 5 moderate-to goodquality prospective cohort studies that included people across the full spectrum of predialysis CKD. [12] [13] [14] [15] [16] We found an independent association between sFLC levels and both mortality and progression to ESRD in an analysis that included conventional risk factors for these outcomes. Moreover, the HR for mortality observed in participants with sFLC levels greater than the upper limit of normal was similar in magnitude to that associated with DM or previous CVD.
Mortality
In a meta-analysis incorporating individual patient data from all 5 studies, we found an independent association between elevated levels of sFLCs and all-cause mortality, which supported the findings of 3 of the individual studies. [14] [15] [16] Although we had only 15 participants (0.4%) with CKD stage G1 in the meta-analysis, the results indicate that sFLC levels may have a role in all stages of predialysis CKD. This is consistent with general population studies identifying an association between elevated sFLC levels and mortality in individuals without CKD. 17, 18 It is not known whether sFLC levels are causally linked to increased mortality in patients with CKD, but there are plausible explanatory mechanisms, including through their association with immune dysfunction. The sFLCs isolated from patients with kidney disease abrogate essential functions of neutrophils, including chemotaxis. 19, 20 Also, sFLCs inhibit neutrophil apoptosis, and so by interfering with the resolution of inflammation may perpetuate a chronic inflammatory state, which has been found to be associated with adverse outcomes in patients with CKD. [19] [20] [21] In addition, sFLCs activate mast cells, which may accelerate atherosclerosis and myocardial fibrosis and can contribute to the development of interstitial fibrosis in the kidney through a range of mechanisms. 22 However, a specific cell receptor for sFLCs has not been identified to date.
23
Contrary to the present findings in predialysis CKD, a study of patients umdergoing hemodialysis found an inverse relationship between sFLC level and mortality, ie, those with higher sFLC levels had lower mortality risk. 24 The authors speculated that higher sFLC levels may reflect less uremia-related bone marrow dysfunction and that increased sFLC levels are associated with improved defense against infection. Further work is needed in the hemodialysis population to validate this study's findings.
24
Progression to ESRD Two studies, with inconsistent results, previously reported the relationship between sFLC level and progression to ESRD and were included in this meta-analysis. 13, 14 We incorporated additional data from a third study and identified a positive independent association between sFLC level and risk of ESRD. 15 High levels of sFLC may directly cause additional kidney damage in those who already have CKD, and thus increase progression risk. Although it is known that monoclonal sFLCs can cause various forms of kidney injury and, in the proximal tubule, can induce pathways linked with inflammation, apoptosis, and fibroblastic differentiation, outside the evidence we summarize herein on the effect of polyclonal sFLCs on leukocyte subsets, there are no published studies reporting a direct mechanism for kidney injury to date. [25] [26] [27] [28] Although it is possible that the associations between sFLC levels and adverse outcomes reflect residual confounding due to the association between sFLC levels and eGFR, there is good supportive evidence for a true independent association of sFLC levels with adverse outcomes.
First, the significant association between sFLC levels and adverse outcomes remained after adjustment for creatinine-based eGFR. In contrast, a recent patient-level meta-analysis found limited additional prognostic value for other alternative markers of glomerular filtration, such as cystatin C, b-trace protein, and b 2 -microglobulin, in analyses that included creatininebased eGFR. 29 Second, in the studies included in this metaanalysis, the correlation between eGFR and sFLC levels (where reported) is moderate (r values of À0.56 and À0.49, respectively). 14, 16 This indicates that although sFLC level is, in part, associated with eGFR, a substantial contribution to differences in sFLC levels is independent of kidney function. For example, sFLCs undergo substantial nonrenal clearance through the reticuloendothelial system, which accounts for a greater portion of clearance in CKD as kidney function declines. 30 Third, the association between sFLC levels and mortality has been reported in studies of a general population with normal kidney function and nonrenal disease, supporting the theory that sFLCs have adverse effects via mechanisms other than through an association with kidney disease, although it remains possible that even in this group the sFLC level partially reflects the spectrum of kidney function. 17, 18, [31] [32] [33] Finally, there are biologically plausible mechanisms for a relationship between sFLC levels and adverse outcomes, for example, through their association with inflammation and reticuloendothelial system health, properties that other renally cleared small molecules, such as b-trace protein and b 2 -microglobulin, do not possess.
The strengths of this study include a broad search strategy, the use of robust methods for study selection and quality assessment, and inclusion of individual patient data from all included studies. Limitations include a limited search of grey literature, which means that we may have missed some studies that had only been reported as conference abstracts, and the inability to conduct a traditional metaanalysis using the 43.3 mg/L cutoff value due to the small numbers of patients with values below this level in 2 of the studies. There may also have been undetected variation in the methods used to collect data in the original studies. The inclusion of at least 1 collaborator from each of the original studies aimed to Further research is needed to identify the biological basis for the associations between sFLC levels and adverse outcomes in CKD and to examine the utility of sFLC levels as a biomarker for enhanced risk stratification. Whether sFLC levels have a role in routine risk stratification in CKD could be addressed by a multicenter validation study with an a priori design that includes a statistical model for incorporating sFLC levels with routine laboratory variables that represent the standard of care. 34 This would allow elucidation of any additional sensitivity and specificity of sFLC levels for risk stratification and the impact of this on clinical and health economic outcomes. Future study designs should take into account the measurement uncertainty (interassay variability) of the Freelite assay. 35 
CONCLUSION
This meta-analysis demonstrated independent associations between sFLC levels and progression to ESRD and mortality in patients with CKD. It provides the basis for further work to explore the biological basis for these associations and to assess whether sFLC level provides incremental value when added to current risk stratification models.
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